Brain Imaging in Type 2 Diabetes

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

Abstract

Type 2 diabetes mellitus (T2D) and dementia are highly prevalent and major public health problems in aging populations. There is a strong association between T2D and incident dementia, and it is possible that this is a causal association. Assuming causality, there may be two major pathways by which T2D increases the risk of developing dementia, namely cerebrovascular disease and neurodegeneration, which may be synergistic or additive. Brain imaging allows the study of these pathways in vivo and can assist in the planning of further mechanistic studies in the field. Brain magnetic resonance imaging (MRI) and positron emission tomography (PET) are the two most valuable modalities that can advance our knowledge in this field. In this chapter, we approach evidence from such studies from a clinical and mechanistic viewpoint rather than a technical imaging perspective. Overall, there appears to be consistent evidence linking T2D to the presence of brain atrophy, reduced white matter integrity, and altered functional brain activation both during resting state and task performance. The impact of cerebrovascular disease as measured by in vivo MRI surprisingly appears to be less consistent and may be influenced by duration and severity of the diabetic phenotype. What remains to be elucidated further is whether T2D can cause disruption of the blood-brain barrier, neuroinflammation, or microinfarction, and thus promote neurodegeneration. The advent of high-field MRI, advanced dynamic contrast imaging, and new PET neuroinflammation ligands may resolve these issues. Large cohort studies using multimodality imaging may assist in clarifying many uncertainties.

Original languageEnglish
Title of host publicationType 2 Diabetes and Dementia
EditorsVelandai Srikanth, Zoe Arvanitakis
Place of PublicationUnited Kingdom
PublisherAcademic Press
Chapter4
Pages49-66
Number of pages18
ISBN (Electronic)9780128096949
ISBN (Print)9780128094549
DOIs
Publication statusPublished - 6 Mar 2018

Keywords

  • Magnetic resonance imaging
  • Neuroimaging
  • Positron emission tomography
  • Type 2 diabetes

Cite this

Moran, C., Beare, R., Phan, T., & Srikanth, V. (2018). Brain Imaging in Type 2 Diabetes. In V. Srikanth, & Z. Arvanitakis (Eds.), Type 2 Diabetes and Dementia (pp. 49-66). United Kingdom: Academic Press. https://doi.org/10.1016/B978-0-12-809454-9.00004-4
Moran, Chris ; Beare, Richard ; Phan, Thanh ; Srikanth, Velandai. / Brain Imaging in Type 2 Diabetes. Type 2 Diabetes and Dementia. editor / Velandai Srikanth ; Zoe Arvanitakis. United Kingdom : Academic Press, 2018. pp. 49-66
@inbook{b49787c2477f4ab4b0447ebaaa68cb8e,
title = "Brain Imaging in Type 2 Diabetes",
abstract = "Type 2 diabetes mellitus (T2D) and dementia are highly prevalent and major public health problems in aging populations. There is a strong association between T2D and incident dementia, and it is possible that this is a causal association. Assuming causality, there may be two major pathways by which T2D increases the risk of developing dementia, namely cerebrovascular disease and neurodegeneration, which may be synergistic or additive. Brain imaging allows the study of these pathways in vivo and can assist in the planning of further mechanistic studies in the field. Brain magnetic resonance imaging (MRI) and positron emission tomography (PET) are the two most valuable modalities that can advance our knowledge in this field. In this chapter, we approach evidence from such studies from a clinical and mechanistic viewpoint rather than a technical imaging perspective. Overall, there appears to be consistent evidence linking T2D to the presence of brain atrophy, reduced white matter integrity, and altered functional brain activation both during resting state and task performance. The impact of cerebrovascular disease as measured by in vivo MRI surprisingly appears to be less consistent and may be influenced by duration and severity of the diabetic phenotype. What remains to be elucidated further is whether T2D can cause disruption of the blood-brain barrier, neuroinflammation, or microinfarction, and thus promote neurodegeneration. The advent of high-field MRI, advanced dynamic contrast imaging, and new PET neuroinflammation ligands may resolve these issues. Large cohort studies using multimodality imaging may assist in clarifying many uncertainties.",
keywords = "Magnetic resonance imaging, Neuroimaging, Positron emission tomography, Type 2 diabetes",
author = "Chris Moran and Richard Beare and Thanh Phan and Velandai Srikanth",
year = "2018",
month = "3",
day = "6",
doi = "10.1016/B978-0-12-809454-9.00004-4",
language = "English",
isbn = "9780128094549",
pages = "49--66",
editor = "Velandai Srikanth and Arvanitakis, {Zoe }",
booktitle = "Type 2 Diabetes and Dementia",
publisher = "Academic Press",
address = "United States",

}

Moran, C, Beare, R, Phan, T & Srikanth, V 2018, Brain Imaging in Type 2 Diabetes. in V Srikanth & Z Arvanitakis (eds), Type 2 Diabetes and Dementia. Academic Press, United Kingdom, pp. 49-66. https://doi.org/10.1016/B978-0-12-809454-9.00004-4

Brain Imaging in Type 2 Diabetes. / Moran, Chris; Beare, Richard; Phan, Thanh; Srikanth, Velandai.

Type 2 Diabetes and Dementia. ed. / Velandai Srikanth; Zoe Arvanitakis. United Kingdom : Academic Press, 2018. p. 49-66.

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

TY - CHAP

T1 - Brain Imaging in Type 2 Diabetes

AU - Moran, Chris

AU - Beare, Richard

AU - Phan, Thanh

AU - Srikanth, Velandai

PY - 2018/3/6

Y1 - 2018/3/6

N2 - Type 2 diabetes mellitus (T2D) and dementia are highly prevalent and major public health problems in aging populations. There is a strong association between T2D and incident dementia, and it is possible that this is a causal association. Assuming causality, there may be two major pathways by which T2D increases the risk of developing dementia, namely cerebrovascular disease and neurodegeneration, which may be synergistic or additive. Brain imaging allows the study of these pathways in vivo and can assist in the planning of further mechanistic studies in the field. Brain magnetic resonance imaging (MRI) and positron emission tomography (PET) are the two most valuable modalities that can advance our knowledge in this field. In this chapter, we approach evidence from such studies from a clinical and mechanistic viewpoint rather than a technical imaging perspective. Overall, there appears to be consistent evidence linking T2D to the presence of brain atrophy, reduced white matter integrity, and altered functional brain activation both during resting state and task performance. The impact of cerebrovascular disease as measured by in vivo MRI surprisingly appears to be less consistent and may be influenced by duration and severity of the diabetic phenotype. What remains to be elucidated further is whether T2D can cause disruption of the blood-brain barrier, neuroinflammation, or microinfarction, and thus promote neurodegeneration. The advent of high-field MRI, advanced dynamic contrast imaging, and new PET neuroinflammation ligands may resolve these issues. Large cohort studies using multimodality imaging may assist in clarifying many uncertainties.

AB - Type 2 diabetes mellitus (T2D) and dementia are highly prevalent and major public health problems in aging populations. There is a strong association between T2D and incident dementia, and it is possible that this is a causal association. Assuming causality, there may be two major pathways by which T2D increases the risk of developing dementia, namely cerebrovascular disease and neurodegeneration, which may be synergistic or additive. Brain imaging allows the study of these pathways in vivo and can assist in the planning of further mechanistic studies in the field. Brain magnetic resonance imaging (MRI) and positron emission tomography (PET) are the two most valuable modalities that can advance our knowledge in this field. In this chapter, we approach evidence from such studies from a clinical and mechanistic viewpoint rather than a technical imaging perspective. Overall, there appears to be consistent evidence linking T2D to the presence of brain atrophy, reduced white matter integrity, and altered functional brain activation both during resting state and task performance. The impact of cerebrovascular disease as measured by in vivo MRI surprisingly appears to be less consistent and may be influenced by duration and severity of the diabetic phenotype. What remains to be elucidated further is whether T2D can cause disruption of the blood-brain barrier, neuroinflammation, or microinfarction, and thus promote neurodegeneration. The advent of high-field MRI, advanced dynamic contrast imaging, and new PET neuroinflammation ligands may resolve these issues. Large cohort studies using multimodality imaging may assist in clarifying many uncertainties.

KW - Magnetic resonance imaging

KW - Neuroimaging

KW - Positron emission tomography

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85047365283&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-809454-9.00004-4

DO - 10.1016/B978-0-12-809454-9.00004-4

M3 - Chapter (Book)

SN - 9780128094549

SP - 49

EP - 66

BT - Type 2 Diabetes and Dementia

A2 - Srikanth, Velandai

A2 - Arvanitakis, Zoe

PB - Academic Press

CY - United Kingdom

ER -

Moran C, Beare R, Phan T, Srikanth V. Brain Imaging in Type 2 Diabetes. In Srikanth V, Arvanitakis Z, editors, Type 2 Diabetes and Dementia. United Kingdom: Academic Press. 2018. p. 49-66 https://doi.org/10.1016/B978-0-12-809454-9.00004-4